Accordingly, compared with traditional CTLA-4 antibody (ipilimumab)- and PD-L1 antibody (atezolizumab or avelumab)-mediated immunotherapy, bifunctional antibody–ligand traps comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFBR2 ectodomain sequence are more effective in reducing tumour-infiltrating Tregs and inhibiting tumour progression in the TME [152]. The gene discussed is CTLA4; the disease is neoplasm.